Dostarlimab is reported to provide long-term benefits in patients with dMMR/MSI-H endometrial cancer. Some outlets suggest that combining dostarlimab with chemotherapy may have curative potential in this patient group, although the treatment's benefits and risks are still being considered. The treatment's efficacy and long-term outcomes are being discussed and presented at various medical conferences.